FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)

Lobbying for DRAGONFLY THERAPEUTICS, INC. · Clinical-stage biopharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $30,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Taxation/Internal Revenue Code

Lobbying related to deductibility of research and development expenses.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.